- How to use
- 1. Hairy cell leukemia
- 2. Multiple myeloma
- 3. Non-Hodgkin's lymphoma
- 4. Chronic myeloid leukemia
- 5. Chronic hepatitis B
- 6. Acute and chronic hepatitis C
- 7. Condylomata acuminata
- Who should not use
- Possible side effects
Recombinant human interferon alpha 2a is a protein indicated for the treatment of diseases such as hairy cell leukemia, multiple myeloma, non-Hodgkin's lymphoma, chronic myeloid leukemia, chronic hepatitis B, acute and chronic hepatitis C and acuminate condyloma.
This remedy is thought to work by inhibiting viral replication and modulating the host's immune response, thereby exerting an antitumor and antiviral activity.
How to use
Recombinant human interferon alfa 2A should be administered by a healthcare professional, who will know how to prepare the drug. The dosage depends on the disease to be treated:
1. Hairy cell leukemia
The recommended daily dose of the drug is 3 MIU for 16 to 20 weeks, given as an intramuscular or subcutaneous injection. It may be necessary to reduce the dose or frequency of injections to determine the maximum tolerated dose. The recommended maintenance dose is 3 MIU, three times a week.
When side effects are severe, it may be necessary to cut the dose in half and the doctor must determine whether or not the person should continue treatment after six months of therapy.
2. Multiple myeloma
The recommended dose of recombinant human interferon alfa 2A is 3 MIU, three times a week, administered as an intramuscular or subcutaneous injection. According to the person's response and tolerance, the dose can be gradually increased up to 9 MIU, three times a week.
3. Non-Hodgkin's lymphoma
In cases of people with non-Hodgkin's lymphoma, the drug can be administered 4 to 6 weeks after chemotherapy and the recommended dose is 3 MIU, three times a week for at least 12 weeks, subcutaneously. When administered in combination with chemotherapy, the recommended dose is 6 MIU / m2, administered subcutaneously or intramuscularly during days 22 to 26 of chemotherapy.
4. Chronic myeloid leukemia
The dose of recombinant human interferon alfa 2A can be gradually increased from 3 MIU daily for three days to 6 MIU daily for three days until the target dose of 9 MIU daily until the end of the treatment period. After 8 to 12 weeks of therapy, patients with a haematological response can continue treatment until complete response or 18 months to 2 years after starting treatment.
5. Chronic hepatitis B
The recommended dose for adults is 5 MIU, three times a week, administered subcutaneously for 6 months. For people who do not respond to recombinant human interferon alpha 2A after one month of therapy, an increase in dose may be necessary.
If, after 3 months of therapy, there is no response from the patient, discontinuation of treatment should be considered.
6. Acute and chronic hepatitis C
The recommended dose of recombinant human interferon alfa 2A for treatment is 3 to 5 MIU, three times a week, administered subcutaneously or intramuscularly for 3 months. The recommended maintenance dose is 3 MIU, three times a week for 3 months.
7. Condylomata acuminata
The recommended dose is a subcutaneous or intramuscular application of 1 MIU to 3 MIU, 3 times a week, for 1 to 2 months or 1 MIU applied at the base of the affected site on alternate days, for 3 consecutive weeks.
Who should not use
This medication should not be used in people who are hypersensitive to any of the components present in the formula, with illness or history of severe heart, kidney or liver disease.
In addition, it should also not be used in women who are pregnant or breastfeeding, unless recommended by the doctor.
Possible side effects
The most common side effects that can occur with the use of this medication are flu-like symptoms, such as tiredness, fever, chills, muscle pain, headache, joint pain, sweating, among others.
